TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06179732

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Mesh - spatial repellent impregnated with transfluthrin (2500mg)
Description: Mesh is one of the first spatial repellent tools to provide long-lasting protection to users, with predicted efficacy of 6-months. The active ingredient of Mesh is transfluthrin, a fast-acting volatile pyrethroid with low persistency, which can act either by killing or via sublethal toxicity that causes deviation (repellency) in host attraction, reducing host-contact and risk of infectious bites. The chemical passively releases into the air and interacts with vector odour receptors causing irritation. The design of Mesh is simple with a transfluthrin-infused sheet protected by plastic mesh and encased in a plastic frame.~Mesh will be distributed to the intervention arm only.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information and Education Campaigns (IEC)
Description: IEC campaigns will formally encourage breeding site management through; good practice household-level water storage (covering and cleaning of water storage containers) and waste management (removal of potential breeding sites in and around the home) using leaflets and word of mouth. IEC will be conducted in both arms.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: test and treat malaria cases
Description: All children in the cohort (both arms) will be tested by rapid diagnostic testing (RDT) monthly. If any children test positive, they will be treated with a course of 3-day artemisinin combination therapy (ACT) according to standard protocol and local guidelines. All children in the cohort will receive ACT to provide clearance of any malaria parasites during the baseline of the study.
Study: NCT05347875

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ICanWALK© App.
Description: App containing educational and instructional videos on crutch fitting and walking with key components of these skills highlighted. App video records individual using the taught skills to enable them and their care providers to review their usage of the walking aids.
Study: NCT05207722

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYNK-101
Description: CYNK-101 is a human placental hematopoietic stem/progenitor cell derived NK cell product, that is genetically modified to express a variant of CD16, Fc gamma receptor III (FcγRIII).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYNK-101
Description: CYNK-101 is a human placental hematopoietic stem/progenitor cell derived NK cell product, that is genetically modified to express a variant of CD16, Fc gamma receptor III (FcγRIII).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg on Day 1 of each 3-week cycle as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg on Day 1 of each 3-week cycle as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 8 mg/kg loading dose and then 6 mg/kg maintenance dose administered IV on day 1 of each 3-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 8 mg/kg loading dose and then 6 mg/kg maintenance dose administered IV on day 1 of each 3-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Interleukin-2
Description: 6 million (M) international units (IU) of rhIL-2 administered subcutaneously (SC) on each CYNK-101 infusion day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Interleukin-2
Description: 6 million (M) international units (IU) of rhIL-2 administered subcutaneously (SC) on each CYNK-101 infusion day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide: 900 mg/m2 administered IV as part of a 3-day lymphodepletion regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide: 900 mg/m2 administered IV as part of a 3-day lymphodepletion regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine: 30 mg/m2 administered IV as part of a 3-day lymphodepletion regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine: 30 mg/m2 administered IV as part of a 3-day lymphodepletion regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: MESNA: shall be administered as part of a 3-day lymphodepletion regimen for the inhibition of hemorrhagic cystitis induced by cyclophosphamide. Route of administration, dosage, and frequency of Mesna should be based on institutional standards.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: MESNA: shall be administered as part of a 3-day lymphodepletion regimen for the inhibition of hemorrhagic cystitis induced by cyclophosphamide. Route of administration, dosage, and frequency of Mesna should be based on institutional standards.
Study: NCT05838950

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high-intensity interval training intervention
Description: Intervention groups include 3 arms with 3 different HIIT protocols to identify optimal exercise regimen for improving cardiometabolic health in young adults with obesity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high-intensity interval training intervention
Description: Intervention groups include 3 arms with 3 different HIIT protocols to identify optimal exercise regimen for improving cardiometabolic health in young adults with obesity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high-intensity interval training intervention
Description: Intervention groups include 3 arms with 3 different HIIT protocols to identify optimal exercise regimen for improving cardiometabolic health in young adults with obesity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high-intensity interval training intervention
Description: Intervention groups include 3 arms with 3 different HIIT protocols to identify optimal exercise regimen for improving cardiometabolic health in young adults with obesity.
Study: NCT06448858

Intervention type: DIAGNOSTIC_TEST
Intervention: serum Mn, Se, iron, Cu & Zn levels
Description: Evaluate the concentration of serum Mn, Se, iron, Cu \& Zn levels in obese and overweight adolescents.

Intervention type: DIAGNOSTIC_TEST
Intervention: serum Mn, Se, iron, Cu & Zn levels
Description: Evaluate the concentration of serum Mn, Se, iron, Cu \& Zn levels in obese and overweight adolescents.

Intervention type: DIAGNOSTIC_TEST
Intervention: serum Mn, Se, iron, Cu & Zn levels
Description: Evaluate the concentration of serum Mn, Se, iron, Cu \& Zn levels in obese and overweight adolescents.
Study: NCT04775576

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pleth Variability Index
Description: Conventional fluid management is widely used in clinical practice. In this method, the fluid need of the patient is decided according to pulse, arterial blood pressure, central venous pressure, urine output and clinical condition. In the targeted fluid therapy method, besides static parameters such as pulse, arterial blood pressure, central venous pressure; Dynamic parameters such as Stroke volume variability (SVV), pulse pressure variability (PPV), pleth variability index (PVI), continuous hemoglobin (SpHb) are also used noninvasively.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional fluid theraphy
Description: 8-10 ml / kg / hour iv fluid maintenance will be started for the control group. If the mean arterial pressure (MAP) is \<65 mmHg or the decrease in MAP is more than 20%, 250 ml iv colloid will be applied. If the decrease in MAP continues despite the colloid bolus or if the MAP is below 65 mmHg, noradrenaline infusion will be started.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Anesthesia method
Description: All patients included in the study will be premedicated with 1mg of midazolam after monitoring with pulse, non-invasive blood pressure, oxygen saturation. Then, invasive arterial cannulation will be applied and continuous blood pressure monitoring will be done. In the PVI group, non-invasive PVI and SpHb monitoring will also be performed from the other upper extremity without arterial cannulation. After two minutes of preoxygenation, anesthesia induction will be started. Anesthesia induction doses used routinely in our clinic include iv 2 mg / kg propofol, 0.6 mg / kg rocuronium and 2 μg / kg fentanyl. Sevoflurane will be administered by inhalation during anesthesia maintenance after tracheal intubation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Anesthesia method
Description: All patients included in the study will be premedicated with 1mg of midazolam after monitoring with pulse, non-invasive blood pressure, oxygen saturation. Then, invasive arterial cannulation will be applied and continuous blood pressure monitoring will be done. In the PVI group, non-invasive PVI and SpHb monitoring will also be performed from the other upper extremity without arterial cannulation. After two minutes of preoxygenation, anesthesia induction will be started. Anesthesia induction doses used routinely in our clinic include iv 2 mg / kg propofol, 0.6 mg / kg rocuronium and 2 μg / kg fentanyl. Sevoflurane will be administered by inhalation during anesthesia maintenance after tracheal intubation.
Study: NCT05048589

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard-Dose Quadrivalent Influenza Vaccine
Description: For the control arm, the standard-dose quadrivalent influenza vaccines Influvactetra® and Vaxigriptetra will be used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-Dose Quadrivalent Influenza Vaccine
Description: For the control arm, the high-dose quadrivalent influenza vaccine Efluelda®/Fluzone® High-Dose Quadrivalent will be used.
Study: NCT04305106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab (7.5mg/kg BW) + Saline (100ml) Bevacizumab will be administered in a single dose with no less than 90 minutes of intravenous infusion under ECG monitoring.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (7.5mg/kg BW) + Saline (100ml) The placebo drug will be administered in a single dose with no less than 90 minutes of intravenous infusion under ECG monitoring.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: Standard care, including prophylactic doses of low molecular weight heparin or unfractionated heparin without contraindications, and therapeutic doses of anticoagulants with the evidence of thrombosis risk or occurrence.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard care
Description: Standard care, including prophylactic doses of low molecular weight heparin or unfractionated heparin without contraindications, and therapeutic doses of anticoagulants with the evidence of thrombosis risk or occurrence.
Study: NCT04927494

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health is Wealth: A Cervical Health Program
Description: Health is Wealth: A Cervical Health Program will be introduced in a one-time 2-hour educational session, participants will be given HPV self-sampling kits, and instructional sheet that visually depicts the steps for self-sampling. The program will be culturally tailored to increase self-efficacy and knowledge while simultaneously addressing perceived health beliefs associated with cervical cancer and barriers associated with cervical cancer screening and HPV self-sampling. Content will be delivered in a group format (about 10-15 participants) by lecture, demonstration, and interactive exercises.
Study: NCT04266704

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sharing Intervention
Description: intervention includes both analytic and socioemotional components related to self-management of hypertension and is specifically targeted to African American women. Along with providing education on lifestyle changes to lower blood pressure, DASH diet, exercise, and medication adherence (analytic components), the intervention is designed to promote social activities around blood pressure self-management, in particular, sharing blood pressure management information with peers (socioemotional components).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sharing Intervention
Description: intervention includes both analytic and socioemotional components related to self-management of hypertension and is specifically targeted to African American women. Along with providing education on lifestyle changes to lower blood pressure, DASH diet, exercise, and medication adherence (analytic components), the intervention is designed to promote social activities around blood pressure self-management, in particular, sharing blood pressure management information with peers (socioemotional components).
Study: NCT05499078

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SULFEX 13081.22
Description: Patients with dry or irritated nose treated with SULFEX 13081.22 nasal spray for 6 days (with at least 1 spray use a day). Severity of the nasal symptoms will be compared before and 6 days after spray use on a 7-point nasal symptoms scale basis.
Study: NCT06107153

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine 100 UNT/ML Pen Injector [Lantus]
Description: Insulin is given as glargine U100 at bedtime in a dose of 10 units. The patients will be given instruction to up-titrate the insulin by adding two units every two days with an aim to reach fasting blood glucose (FBG) between 80 - 130 mg/dl using a home glucometer. And to down-titrate the insulin by subtracting two units when the FBG is below 80 mg/dl. The patients continued on basal insulin for two weeks or less when FBG is persistently below 100 mg/dl on a dose of 10 units of insulin Glargine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saxagliptin 2.5 mg/ Metformin Hydrochloride extended release 1000 mg
Description: Saxagliptin 2.5 mg/ Metformin Hydrochloride extended release 1000 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saxagliptin 2.5 mg/ Metformin Hydrochloride extended release 1000 mg
Description: Saxagliptin 2.5 mg/ Metformin Hydrochloride extended release 1000 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone 30mg
Description: Pioglitazone 30mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone 30mg
Description: Pioglitazone 30mg
Study: NCT05014581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Noradrenaline
Description: Pre-emptive continuous infusion of noradrenaline during the peri-intubation period
Study: NCT05548491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZR-MD-001 ointment/semi-solid drug
Description: ointment/semi-solid drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AZR-MD-001 ointment/semi-solid drug
Description: ointment/semi-solid drug
Study: NCT05760222

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture for prevention/early treatment of vasomotor symptoms and sleep impairment in LHRHa induced amenorrhea in Breast Cancer patients
Study: NCT05426824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase（P-GOD）
Description: stage I/II) ENKTL patients receiving P-GOD for the first time, gemcitabine 1000 mg/m2 intravenously on day 1 and day 5, oxaliplatin 75 mg/m2 intravenously on day 1, dexamethason 40 mg intravenously on day 1-4, and pegaspargase 3750 IU intramuscularly on day 2. The cycle was repeated every 21 days.The activity of pegaspargase in peripheral blood will be detected on D3, D4, D5, D6, D7, D8, D10, D12, D14, D16, D18 and D21.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase（PEMD）
Description: stage III/IV ENKTL patients receiving PEMD for the first time,methotrexate 3.0 g/m2 intravenously over 6 h on day 1, etoposide 100 mg/m2 intravenously on days 2-4, dexamethasone 40 mg intravenously on days 1-4, pegaspargase 3750 IU intramuscularly on day 2. The activity of pegaspargase in peripheral blood will be detected on D3, D4, D5, D6, D7, D8, D10, D12, D14, D16, D18 and D21.
Study: NCT04963959

Intervention type: DEVICE
Group type: OTHER
Intervention: Peripheral blood mononuclear cell apheresis
Description: mononuclear cell donation for tumor immunotherapy study of UCAR-T cells
Study: NCT05422209

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mesh-augmented sacrospinal fixation with posterior colporrhaphy and perineoplasty.
Description: Vaginal mesh-augmented sacrospinal fixation with posterior colporrhaphy and perineoplasty.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mesh-augmented sacrospinal fixation with posterior colporrhaphy.
Description: Vaginal mesh-augmented sacrospinal fixation with posterior colporrhaphy.
Study: NCT05813535

Intervention type: DRUG
Group type: OTHER
Intervention: Sodium bicarb lock
Description: 8.4% sodium bicarb locks when off venous nutrition
Study: NCT06308549

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyDiaMate
Description: MyDiaMate programme
Study: NCT04777448

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: telerehabilitation
Description: 24 sessions (less Thant 1h hour each) of tele rehabilitation. Patients can choose among several activities (gym, dance, cardio training, ...)
Study: NCT06088251

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutri Training
Description: Nutri Training will begin with 1) a presentation of diet counseling evidence and best practices for advising patients, along with information about nutrition recommendations for patients with chronic illness and 2) tools supporting the patient for follow-up. This content will be delivered via a live demonstration of the Nutri interactive software and case demonstration, a novel approach to delivering the learning objectives of standard nutrition education for residents.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Nutrition Education
Description: Standard Nutrition Education Standard Nutrition Training will present an overview of 1) nutrition recommendations for patients with chronic disease and 2) cover the role of a registered dietitian and referrals.
Study: NCT05359770

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active HD-tDCS
Description: Experimental group: 10-sessions of anodal HD-tDCS ( tDCS 1x1, developed by Soterix Medical Inc.) associated to respiratory training; for 20 minutes (each session). It will be delivered a 3mA intensity electrical current accordingly 10/20 International System on cortical representation zone of left diaphragmatic motor cortex using HD-tDCS.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Active HD-tDCS
Description: Experimental group: 10-sessions of anodal HD-tDCS ( tDCS 1x1, developed by Soterix Medical Inc.) associated to respiratory training; for 20 minutes (each session). It will be delivered a 3mA intensity electrical current accordingly 10/20 International System on cortical representation zone of left diaphragmatic motor cortex using HD-tDCS.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control group
Description: Sham Control: 10-sessions of anodal HD-tDCS( tDCS 1x1, developed by Soterix Medical Inc.) associated to respiratory training; for 20 minutes (each session) with a 3mA intensity. The device will provide a 30-second ramp-up followed immediately by a 30-second ramp down.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control group
Description: Sham Control: 10-sessions of anodal HD-tDCS( tDCS 1x1, developed by Soterix Medical Inc.) associated to respiratory training; for 20 minutes (each session) with a 3mA intensity. The device will provide a 30-second ramp-up followed immediately by a 30-second ramp down.
Study: NCT04947995

Intervention type: DEVICE
Intervention: ctDNA multi-omics test
Description: The ctDNA multi-omics test for gastric cancer will be built based on low-pass WGS, methylation, and target region sequencing.

Intervention type: DEVICE
Intervention: ctDNA multi-omics test
Description: The ctDNA multi-omics test for gastric cancer will be built based on low-pass WGS, methylation, and target region sequencing.

Intervention type: DEVICE
Intervention: ctDNA multi-omics test
Description: The ctDNA multi-omics test for gastric cancer will be built based on low-pass WGS, methylation, and target region sequencing.
Study: NCT05449938

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and root planing
Description: Scaling and root planing involves removal of plaque and calculus on tooth surface.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and root planing
Description: Scaling and root planing involves removal of plaque and calculus on tooth surface.
Study: NCT00365001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 10mg/kg iv on day 8

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tocilizumab [RoActemra/Actemra]
Description: 10mg/kg iv on day 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 10-25mg po/week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: 10-25mg po/week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: 40mg po on days 1, 15 and 43
Study: NCT05848596

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: hand hygiene theoretical training
Description: Hand hygiene theoretical training~* Powerpoint presentation,~* How to ensure hand hygiene according to the demonstration method,

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hand hygiene theoretical + simulation training
Description: Hand hygiene theoretical training~* Powerpoint presentation,~* How to ensure hand hygiene according to the demonstration method,~Hand hygiene simulation training will be carried out by the researcher in an environment with a sink.~* Simulation-based training on standard patients,~* Hand hygiene application and important points to be considered during the application will be emphasized.
Study: NCT04978805

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Relaxation Exercise
Description: In the progressive relaxation technique, the tension and anxiety in skeletal muscles are relatively relieved.